Annex 1
THE WELLCOME TRUST POLICY ON FUNDING FOR
CANCER RESEARCH
PREAMBLE
A. The Wellcome Trust supports a wide range of
fundamental, applied and strategic research in the biomedical
sciences relating to human and animal health. Much of the fundamental
research in cell and molecular biology funded by the Trust may
well contribute to new understanding of malignant disease.
B. Considerable support for cancer research,
an in particular for clinical trials, is available from other
funders in the UK.
C. The Trust therefore considers proposals
for funding research grants in the UK on cancer only where the
research could have broader relevance to the understanding of
biological processes or of other diseases.
D. The Trust works in partnership with other
funding agencies on research programmes associated with cancer
where appropriate. Examples are the Institute of Cancer and Development
Biology at the University of Cambridge in collaboration with the
Cancer Research Campaign; and the Cancer Genome Project at the
Sanger Centre in collaboration with the Institute of Cancer Research
and others.
E. The Wellcome Trust has established the
Development Fund administered by Catalyst BioMedica Limited. Its
purpose is to support applied research programs that have potential
for the improvement of healthcare, including those related to
cancer, with the aim of "bridging the gap" between fundamental
research and commercial product development.
With regard to cancer research the Wellcome Trust
considers proposals for:
3. Research relevant to veterinary medicine
including cancer.
4. Research on the history of medicine related
to all diseases including cancer.
5. Applications to the Development Fund for
applied cancer research which also inform the understanding of
biological processes.
With regard to cancer research the Wellcome Trust
does not consider proposals for:
6. UK-based, clinical cancer research in
humans.
As part of its corporate planning process, the
Trust will continue to keep this policy under review.
| 
